Beigene Ltd ADR (NQ: BGNE )
152.03
-1.61
(-1.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Press Releases about Beigene Ltd ADR
![](https://mms.businesswire.com/media/20230526005277/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230525005611/en/1803602/22/Lai_Wang.jpg)
![](https://mms.businesswire.com/media/20230524005324/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230516005958/en/1795637/5/MAX_LogoFullColorRGB.jpg)
![](https://mms.businesswire.com/media/20230506005006/en/1775305/22/BeiGene_sunny.jpg)
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230504005408/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230425006180/en/1775322/22/BeiGene_sunny.jpg)
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230424005816/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230420005320/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230417005339/en/1764923/22/SpringWorks_Logo.jpg)
![](https://ml.globenewswire.com/media/03870757-75d0-4869-a7a0-98e8d7ffbc21/small/swtxlogo-jpg.jpg)
Via GlobeNewswire
![](https://mms.businesswire.com/media/20230417005338/en/1764924/22/MapKure_logo.jpg)
![](https://www.globenewswire.com/Content/Images/intrado.png)
Via GlobeNewswire
![](https://mms.businesswire.com/media/20230413005329/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230330005198/en/1751464/22/Julius_Pryor.jpg)
![](https://mms.businesswire.com/media/20230321005124/en/1742432/5/BeiGene_Hopewell.jpg)
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230227005334/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From BeiGene, Ltd.
Via Business Wire
![](https://mms.businesswire.com/media/20230224005112/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
February 24, 2023
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230224005039/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
February 24, 2023
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230203005094/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230201005204/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene to Present at Upcoming Investor Conferences
February 01, 2023
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230119005888/en/1691219/22/Brukinsa_carton_bottle_capsules.jpg)
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230119005082/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230118005571/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
January 18, 2023
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20230117006065/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230104005542/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
From BeiGene
Via Business Wire
![](https://mms.businesswire.com/media/20221230005150/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20221213005484/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.